Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 8/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.38 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12176980 | 0.81 | CYP17A1 (0.80) | CYP17A1CYP1A2IDO1DYRK1AFYN | |
| SCHEMBL14694367 | 0.76 | CYP17A1 (1.00) | CYP17A1CYP1A2ALDH1A1IDO1SMN1; SMN2 | |
| SCHEMBL2590693 | 0.75 | CYP17A1 (0.64) | CYP17A1CYP1A2 | |
| SCHEMBL2591159 | 0.73 | CYP17A1 (0.51) | CYP17A1CYP1A2CYP2A6ALDH1A1CYP3A4 | |
| SCHEMBL11164485 | 0.72 | HTT (0.49) | CYP17A1CYP1A2CYP2A6ALDH1A1CYP3A4 | |
| SCHEMBL14694960 | 0.71 | CYP17A1 (0.71) | CYP17A1CYP1A2IDO1TDO2FYN | |
| SCHEMBL14694401 | 0.71 | CYP17A1 (0.71) | CYP17A1CYP1A2IDO1TDO2DYRK1A | |
| SCHEMBL2581529 | 0.70 | KDR (0.48) | CYP17A1CYP1A2CYP2A6ALDH1A1CYP3A4 | |
| SCHEMBL14694366 | 0.70 | CYP17A1 (0.83) | CYP17A1CYP1A2IDO1DYRK1ADYRK3 | |
| SCHEMBL334755 | 0.68 | CYP2A6 (0.56) | CYP1A2CYP2A6ALDH1A1CYP3A4NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145419-B2 | Imidazopyridazinyl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-09-29 | — | — | US | disclosed |
| US-9145419-B2 | Imidazopyridazinyl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-09-29 | — | — | US | disclosed |
| US-9145419-B2 | Imidazopyridazinyl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-09-29 | — | — | US | disclosed |
| EP-2563792-B1 | IMIDAZOPYRIDAZINYL COMPOUNDS AND THEIR USES FOR CANCER | BRISTOL MYERS SQUIBB CO (US) | 2014-08-27 | — | — | EP | disclosed |
| EP-2563792-B1 | IMIDAZOPYRIDAZINYL COMPOUNDS AND THEIR USES FOR CANCER | BRISTOL MYERS SQUIBB CO (US) | 2014-08-27 | — | — | EP | disclosed |
| EP-2563792-A1 | IMIDAZOPYRIDAZINYL COMPOUNDS AND THEIR USES FOR CANCER | Bristol-Myers Squibb Company (US) | 2013-03-06 | — | — | EP | disclosed |
| US-20130045980-A1 | IMIDAZOPYRIDAZINYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-21 | — | — | US | disclosed |
| US-20130045980-A1 | IMIDAZOPYRIDAZINYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-21 | — | — | US | disclosed |
| US-20130045980-A1 | IMIDAZOPYRIDAZINYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-21 | — | — | US | disclosed |
| WO-2011137155-A1 | IMIDAZOPYRIDAZINYL COMPOUNDS AND THEIR USES FOR CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-03 | — | — | WO | disclosed |
| WO-2011137155-A1 | IMIDAZOPYRIDAZINYL COMPOUNDS AND THEIR USES FOR CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045980-A1 | IMIDAZOPYRIDAZINYL COMPOUNDS | CYP2C19, CYP3A7, CYP2C18 | CYP17A1 54/4885CYP1A2 9/4885CYP2A6 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.